Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors by Schneider, Anna et al.
2310–2322 Nucleic Acids Research, 2016, Vol. 44, No. 5 Published online 4 February 2016
doi: 10.1093/nar/gkw060
Biochemical characterization of a multi-drug resistant
HIV-1 subtype AG reverse transcriptase: antagonism
of AZT discrimination and excision pathways and
sensitivity to RNase H inhibitors
Anna Schneider1, Angela Corona2, Imke Spo¨ring3, Mareike Jordan1, Bernd Buchholz4,
Elias Maccioni2, Roberto Di Santo5, Jochen Bodem3, Enzo Tramontano2 and Birgitta
M. Wo¨hrl1,*
1Universita¨t Bayreuth, Lehrstuhl Biopolymere und Forschungszentrum fu¨r Bio-Makromoleku¨le, Universita¨tsstrasse
30, 95447 Bayreuth, Germany, 2Department of Life and Environmental Sciences, University of Cagliari, Cittadella
Universitaria di Monserrato, SS 554, 09042, Monserrato, Cagliari, Italy, 3Julius-Maximilians-Universita¨t Wu¨rzburg,
Institut fu¨r Virologie und Immunbiologie, Versbacher Strasse 7, 97078 Wu¨rzburg, Germany, 4Universita¨t Heidelberg,
Medizinische Fakulta¨t Mannheim, Klinik fu¨r Kinder- und Jugendmedizin, Theodor-Kutzer-Ufer 1–3, 68167 Mannheim,
Germany and 5Dipartimento di Chimica e Tecnologie del Farmaco, Istituto Pasteur-Fondazione Cenci Bolognetti,
"Sapienza" Universita` di Roma, Rome, I-00185, Italy
Received July 23, 2015; Revised January 21, 2016; Accepted January 24, 2016
ABSTRACT
We analyzed a multi-drug resistant (MR) HIV-1 re-
verse transcriptase (RT), subcloned from a patient-
derived subtype CRF02 AG, harboring 45 amino acid
exchanges, amongst them four thymidine analog
mutations (TAMs) relevant for high-level AZT (azi-
dothymidine) resistance by AZTMP excision (M41L,
D67N, T215Y, K219E) as well as four substitutions
of the AZTTP discrimination pathway (A62V, V75I,
F116Y and Q151M). In addition, K65R, known to an-
tagonize AZTMP excision in HIV-1 subtype B was
present. Although MR-RT harbored the most signif-
icant amino acid exchanges T215Y and Q151M of
each pathway, it exclusively used AZTTP discrimi-
nation, indicating that the two mechanisms are mu-
tually exclusive and that the Q151M pathway is ob-
viously preferred since it confers resistance to most
nucleoside inhibitors. A derivative was created, ad-
ditionally harboring the TAM K70R and the rever-
sions M151Q as well as R65K since K65R antago-
nizes excision. MR-R65K-K70R-M151Q was compe-
tent of AZTMP excision, whereas other combinations
thereof with only one or two exchanges still pro-
moted discrimination. To tackle the multi-drug resis-
tance problem, we tested if the MR-RTs could still be
inhibited by RNase H inhibitors. All MR-RTs exhib-
ited similar sensitivity toward RNase H inhibitors be-
longing to different inhibitor classes, indicating the
importance of developing RNase H inhibitors further
as anti-HIV drugs.
INTRODUCTION
Patients infected with human immunodeficiency virus
(HIV) are usually treated with a combination therapy of
three or more antiretroviral drugs that belong to different
inhibitor classes. However, the outcome of such a highly ac-
tive antiretroviral therapy (HAART) depends on the sensi-
tivity of the virus to the drugs as well as on the drug ad-
herence of the patient. Lack of compliance often results in
the occurrence of drug resistant virus and the need for other
antiviral treatment regimens. Among the resistance associ-
ated mutations, thymidine analog mutations (TAMs) are of
great importance due to the administration of zidovudine
(azidothymidine, AZT) and/or stavudine (d4T) as the nu-
cleoside reverse transcriptase inhibitor (NRTI) substances
of HAART. Most importantly, TAMs also generate cross-
resistance to other NRTIs (1–3).
Two different mechanisms confer HIV resistance against
AZT. The mutant AZT-resistant reverse transcriptase (RT)
can either selectively excise the already incorporated AZT
monophosphate (AZTMP) in the presence ofATP, thus cre-
ating an AZT-P4-A dinucleotide (1–4) or it can discrimi-
nate between theNRTI triphosphate and the corresponding
dNTP. While HIV type 1 (HIV-1) preferentially uses the ex-
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cision pathway, the predominant resistance mechanism of
HIV-2 is discrimination (5,6).
Excision of the incorporated inhibitor is due to five
primary resistance substitutions (M41L, D67N, K70R,
T215F/Y and K219Q/E) also called TAMs because they
emerge upon treatment with the thymidine analogs AZT
and stavudine (d4T). The major TAM T215Y results in -
 stacking of the aromatic rings of ATP and Tyr and it
is thus essential for AZTMP excision (4). In HIV-1 sub-
type B a sixth TAM, L210W, often occurs together with
M41L and T215Y and contributes substantially to high-
level AZT resistance (7,8). While AZT and d4T are good
substrates for the excision reaction, cytidine analogues, e.g.
zalcitabine (ddC) or lamivudine (3TC), are removed rather
inefficiently (2,9). In HIV-2, AZT discrimination is char-
acterized by the mutations A62V, V75I, F77I, F116Y and
Q151M. Among these, Q151M is the most important muta-
tion. Thus the mutation pattern is also called Q151Mmulti-
drug resistance (MDR) complex (6,10).
Q151M alone or the Q151MMDR complex also emerge
in HIV-1 upon treatment with inhibitors that are poor
substrates for the excision reaction, since Q151M confers
multi-NRTI resistance to most NRTIs and nucleotide RT
inhibitors (NtRTIs), except tenofovir disoproxil fumarate
(TDF) (11,12). Q151M is usually the first mutation to ap-
pear followed by at least two additional amino acid ex-
changes of the Q151M MDR complex (13). Q151M has
been detected in HIV-1 upon combination chemotherapy
with AZT plus didanosine (ddI) or ddC. About 5% of pa-
tients treated with NRTIs acquire this mutation. Similar to
HIV-2, Q151M in HIV-1 appears to impede the incorpora-
tion of AZTTP rather than enhancing the excision of incor-
porated AZTMP (6,10,11,14–17).
Furthermore, treatment with d4T appears to be directly
associated with Q151M and in addition K65R (15). Both
amino acid exchanges result in slower incorporation rates
for NRTIs relative to the corresponding natural dNTPs
(18–21). While Q151M and K65R are positively associ-
ated to each other, the occurrence of K65R antagonizes nu-
cleotide excision caused by TAMs since it interferes with
ATP binding, necessary for NRTI excision (21–23). The re-
duced rate of excision is most pronounced for AZT. How-
ever, transient kinetic analyses showed that the combina-
tion of TAMs and K65R also decreases the ability of the
RT to discriminate against NRTIs. Thus, in the context of
TAMs, K65R leads to a counteraction of excision and dis-
crimination, resulting in AZT susceptibility (19,23). Struc-
tural analyses of a K65R RT indicate that the guanidinium
planes of K65R and the conserved residue R72 are stacked,
thereby forming a molecular platform which restricts rota-
tion of both residues. Consequently, the adaptability of the
polymerase active site is restricted, which impairs both sub-
strate incorporation and NRTI excision (21,24,25).
Here, we report the biochemical characterization of the
recombinant RT enzyme of a patient-derived, multi-drug
resistant (MR) HIV-1 subtype AG circulating recombinant
form CRF02 AG (26). Subtype AG is responsible for about
5% of HIV-1 cases in Europe (27). Before isolation of the
MR-RT the patient was treated over a time span of 12 years,
beginning in 1997, with various combinations of NRTIs
and non-nucleosideRT inhibitors (NNRTIs), i.e. AZT, d4T,
abacavir (ABC), ddI, lamivudine (3TC) and the NNRTI
efavirenz (EFV) (26). Amongst the 45 amino acid exchanges
in theMR-RT compared to the CRF02 AGWTRT, TAMs
for the excision pathway as well as discriminationmutations
from the Q151MMDR complex, and in addition K65R are
present. Moreover, MR-RT harbors the G190E mutation
conferring resistance against NNRTIs, whereas several of
the other exchanges have been identified as compensatory
mutations in subtype B RT which help to improve the repli-
cation capacity of the virus (18,28).
Although in HIV-1 subtype B treatment with AZT re-
sults in the occurrence of TAMs, resistance to most other
NRTIs, e.g. ABC, ddI and TDF is achieved via the discrim-
ination pathway, which also confers resistance to AZT and
thus might lead to the disappearance of TAMs. We there-
fore compared the MR-RT with the corresponding subtype
CRF02 AG WT RT and investigated whether the patient-
derived MR-RT exhibits AZT resistance and whether both
AZT resistance mechanisms are still functional, indicating
an additive effect.We also characterized the polymerization
behavior and fidelity of thewild-type (WT) andMR-RT.Al-
though all drugs administered against RT targeted the poly-
merase domain, there are seven amino acid substitutions
localized in the ribonuclease H (RNase H) domain. There-
fore, we determined the RNase H activities and analyzed
the inhibitory effect of several not yet approved RNase H
inhibitors (RHIs) effective against subtype B RT. Our re-
sults imply that RHIs might be useful in the treatment of
multi-drug resistant HIV strains.
MATERIALS AND METHODS
Cloning, expression and protein purification
RT encoding sequences from a patient derived plasma sam-
ple were amplified by RT-PCR using mouse leukemia virus
RT and Phusion DNA Polymerase (NEB, Germany). RT-
PCR products were gel purified and cloned into Topo-
XL vectors (Invitrogen-Thermo Fisher, USA). Nucleotide
sequences of 10 insert containing single clones were de-
termined, and all encoded the same resistance associated
mutations as the genotypic pool sequences. Cloning and
sequencing was repeated from a second patient derived
plasma sample to ensure the sequence quality and to ex-
clude recombination during the RT reaction. The cod-
ing regions of the CRF02 AG WT RT subunits p66 and
p51 were amplified from pBD6–15 (Genbank Acc. No
AY271690) (29). The amplified coding regions of WT and
MR-RT (GenBank Acc. No. KT581450) were cloned into
the pACYCDuetTM-1 vector (Novagen, Darmstadt, Ger-
many), using restriction enzyme cleavage sites NcoI and
BamHI for p51 or BglII and XhoI for p66, respectively. Co-
expression was performed in Escherichia coli strain BL21
Star (DE3) (Invitrogen-ThermoFisher,USA) inLuria broth
at 37◦C in the presence of chloramphenicol (34 g/ml).
After induction with 500 M isopropyl-thiogalactoside
(IPTG) the temperature was reduced to 25◦C and protein
overexpression was performed overnight. The heterodimers
contained a 6× His tag at the N-terminus of the p51 sub-
unit. The p66/6×His-p51 heterodimers of WT and MR-
RT were purified via Ni-affinity chromatography (HisTrap,
GE Healthcare, Munich, Germany) followed by heparin
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affinity chromatography (HiTrap heparin, GE Healthcare,
Munich, Germany), which allowed the removal of 6×His-
p51 homodimers. Judged by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis and Coomassie stain-
ing the purified proteins contained approximately equal
amounts of p66 and p51.
Mutagenesis
Site-directed mutagenesis was performed according to the
Quick Change mutagenesis protocol (Agilent Technologies,
Santa Clara, CA, USA). After introduction of the required
mutation into the p66 gene using plasmid pACYCDuet-1-
p66, the mutated gene served as a template for p51 gene am-
plification. The mutated p51 gene was then cloned into the
corresponding pACYCDuet-1-p66, resulting in a plasmid
encoding the mutated p66 and p51 sequences.
5′ end-labeling of primers
5′ 32P-end-labeling of the P30 primer (P30) (5′-
GCTGTAATGGCGTCCCTGTTCGGGCGCCTC),
as well as the corresponding AZTMP terminated
P30 primer (P30-AZTMP) or the DNA primer P17 (5′-
GTAAAACGACGGCCATG) (biomers.net; Ulm, Ger-
many) was done as described previously (30).
Polymerase fidelity measurements
Fidelity assays were performed using the 5′ [32P]-end-
labeled P30 DNA primer which was hybridized to
one of the four 50mer DNA templates T50dX with
different sequences in the single-stranded regions
(T50dA 5′–GCTGTGGCCGGTCTCTTGTAGAGG
CGCCCGAACAGGGACGCCATTACAGC), (T50dC
5′-GGTGTGGAA AATGTGATGGCGAGGCGC
CCGAACAGGGACGCCATTACAGC), (T50dG
5′-ACTTTACAAAATCTCATCCGGAGGCGCC
CGAACAGGGACGCCATTACAGC), (T50dT 5′-
GCGACGGAAAAGCCCAGGCTGAGGCGCCCGAA
CAGGGACGCCATTACAGC) (biomers. net; Ulm, Ger-
many). A total of 20 nM of each 32P-P30/T50dX substrate
were pre-incubated in reaction buffer [50 mM Tris/HCl,
pH 8.0, 80 mM KCl, 6 mM MgCl2, 0.5 mM dithiothreitol
(DTT)] for 2 min at 37◦C with 0.08 U of pyrophosphatase
(Sigma Aldrich Chemie GmbH, Taufkirchen, Germany)
and 1.25 mM of the first mismatched or matched dNTP as
a control. Reactions were started by the addition of 1.25
M RT enzyme and stopped after 10 min at 37◦C with an
equal volume of urea loading buffer [0.1% bromophenol
blue, 0.1% xylene cyanol, 8 M urea, 89 mM Tris/HCl pH
8.3, 89 mM boracic acid, 25 mM ethylenediaminetetraac-
etate (EDTA)]. Reaction products were separated on a
denaturing 10% polyacrylamide/8 M urea gel, visualized
by phosphoimaging (Du¨rr Medical CR 35 Bio; Bietigheim-
Bissingen, Germany) and quantified densitometrically
with the software AIDA Image Analyzer V.450 (raytest,
Staubenhardt, Germany). Since all products longer than
P31 comprise the first correct dTTP incorporation they were
also included in quantification of the primer extensions as
described previously (31).
DNA-dependent DNA polymerase activity assay
A total of 100 pmol of 5′ [32P]-end-labeled 17-mer DNA
primer (30) were annealed to single stranded M13mp18
DNA (New England BioLabs, Frankfurt, Germany).
Primer elongation was performed in a total volume of 10
l of reaction buffer (see above) in the presence of 30 nM
[32P]-P17/M13mp18 and 200MdNTPs.After the addition
of 83 nMRT the reaction was carried out for 1, 3 and 6 min
at 37◦C and stopped by adding 10 l urea loading buffer.
Polymerization products were separated and visualized as
described above.
Quantitative polymerization assay
RT polymerase activities were measured with 80 MdTTP,
12 nM of RT enzyme and 100 ng/ml poly(rA)/oligo(dT)16
in a total volume of 25 l according to the instructions of
the EnzChek RT assay kit (Invitrogen Life Technologies,
Darmstadt, Germany). Reactions were started by the ad-
dition of the RT variant, incubated for 10 min at 37◦C and
stopped with 15 mM EDTA. Elongation products were de-
tected by the addition of PicoGreen and measured with a
Synergy 2 microplate reader at 502/523 nm using the reader
softwareGen5 2.0 (BioTek,Winooski, Vermont, USA). For
quantification a standard curve was generated with double
stranded lambda DNA (100–1 ng/ml dsDNA) (EnzChek,
Invitrogen Life Technologies, Darmstadt, Germany). The
specific activities of the polymerization reactions are given
in Units (U), where 1 U corresponds to the incorporation
of 1 nmol TMP by 1 mg of enzyme within 10 min at 37◦C.
Fluorescence equilibrium titrations
To determine the dissociation constant (KD) a
6-carboxyfluorescein (6-FAM) labeled 22/34-
mer DNA/DNA substrate (primer 5′-6FAM-
GGCGTCCCTGTTCGGGCGCCT, template 5′-
CGGTCTCTTGTAAAGGCGCCCGAACAGGGACGCC)
(Metabion GmbH, Planegg-Martinsried, Germany) was
used. Fluorescence equilibrium titrations were performed
on a Fluorolog-Tau-3 spectrofluorometer (HORIBA
JobinYvon GmbH, Unterhaching, Germany) at 25◦C
with 8 nM substrate and increasing amounts of enzyme
(excitation 484 nm, emission 517 nm, slit width 3 nm).
KD-values were calculated via non-linear curve fitting of
the normalized fluorescence data to a two component
binding equation:
F = Fs +
⎧⎪⎪⎨
⎪⎪⎩
(FES − FS) ·
(
KD + [E] + [S] −
√
(KD + [E] + [S])2 − (4 · [S] · [E])
)
2 · [S]
⎫⎪⎪⎬
⎪⎪⎭
FS and FES, fluorescence of the free and enzyme bound sub-
strate; F, observed fluorescence value, [E], enzyme concen-
tration; [S], substrate concentration, KD, dissociation con-
stant.
AZTMP excision
The P30 DNA primer was [32P]-end-labeled, termi-
nated with AZTTP and purified as described (31).
[32P]-P30-AZTMP was hybridized to a T50 template DNA
(5′-GCTGTGGAAAATCTCATGCAGAGGCGCC
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CGAACAGGGACGCCATTACAGC) (30). A total of
20 nM P30-AZTMP/T50, 0.01 U/l of pyrophosphatase
(Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany)
and 5 mM ATP (Jena Bioscience, Jena, Germany) were
pre-incubated for 5 min at 37◦C in reaction buffer in a total
volume of 20 l. AZTMP excision reactions were started
by the addition of 600 nM enzyme, carried out for 30 min
at 37◦C and stopped by adding 20 l of urea loading buffer
(31,32). Excision products and educts were separated via
denaturing gel electrophoresis (8% polyacrylamide/8 M
urea gels) and analyzed as described above.
AZTTP discrimination
The 5′ [32P]-end-labeled P30 primer was hybridized to the
T50 template. In a total volume of 25 l, 100 nM of
[32P]-P30/T50 substrate, 1 MAZTTP or TTP, respectively,
and 0.01 U/l pyrophosphatase (Sigma-Aldrich Chemie
GmbH, Taufkirchen, Germany) were pre-incubated for 5
min at 37◦C. Reactions were started by the addition of 200
nM enzyme, incubated for another 30 s and stopped by
adding 20 l urea loading buffer. Products and educts were
separated on a denaturing 10% polyacrylamide/8 M urea
gel and visualized and quantified as described above.
Determination of KM and vmax
Reactions were performed according to the discrimination
assay in presence of increasingAZTTP concentrations from
1.5 nM to 50 M. Reaction products were separated by de-
naturing gel electrophoresis, and data were fitted using the
fitting program GraFit 5.0.12 (Erithacus Software limited,
West Sussex, UK) and the Michaelis–Menten equation and
as previously described (31).
RNase H activity determination and inhibitor testing
HIV RT-associated RNase H activity assays were per-
formed as described (33,34). Briefly, RT associated RNase
H activity was measured in 100 l reaction volume con-
taining 50 mM Tris/HCl, pH 7.8; 6 mM MgCl2; 1 mM
DTT; 80 mM KCl; 0.25 M RNA/DNA hybrid (5′-
GAUCUGAGCCUGGGAGCU-FLUORESCEIN-3′, 5′-
DABCYL-AGCTCCCAGGCTCAGATC-3′). The reac-
tion mixture was incubated for 1 h at 37◦C, then stopped
by the addition of 50 l EDTA 0.5 M, pH 8.0. Products
were quantified with a Victor 3 plate reader (Perkin Elmer)
at 490/528 nm. Different amounts of enzyme were used
according to a linear range of a dose-response curve: 3.7
nM WT (subtype AG), 3.7 nM MR, 11.1 nM MR-70R,
11.1 nMMR-65K-70R, 33.3 nMMR-RT-70R-151M, 11.1
nMMR-RT-65K-70R-151Q and 33.3 nMHIV-1 subtype B
AZTres-B RT. RHI testing was performed as described pre-
viously (35). All experiments were done at least three times.
Qualitative DNA polymerase-independent RNase H activity
Qualitative RNase H activity was determined as re-
ported previously (36). Cleavage of a non-specific sub-
strate was performed with a 29 nucleotides (nt) Cy5-
labeled RNA (5′- Cy5-AGUCUGAGCCUGGGAGCAG
CCUGGGAGCU-3′ hybridized to a 29 nt DNA 3′-TCA
GACTCGGACCCTCGTCGGACCCTCGA-5′). The re-
action was initiated by adding 1 l of 100 mM MgCl2 to 9
l of reaction mixture containing 50 mMTris–HCl, pH8.0,
80 mMKCl, 2 mMDTT, 200 nM substrate and 3.7, 11.1 or
33.3 nM of enzyme. The sample was incubated at 37◦C for
10 min and the reaction was quenched with 10 l of loading
buffer (8M Urea in TBE buffer). Hydrolysis products were
separated by denaturing polyacrylamide gel electrophore-
sis and visualized by fluorescence imaging (ChemiDoc, Bio-
Rad, Hercules, CA, USA)
Kinetic efficiency of the DNA polymerase-independent
RNase H
Kinetic analysis of the DNA-polymerase indepen-
dent RNase H activity was performed according to
Lineaweaver–Burk plots with the Sigmaplot10 software.
Velocity () was expressed as fmoles/min.
RESULTS AND DISCUSSION
Temporal evolution of drug resistance mutations
The MR HIV-1 CRF02 AG patient isolate from July 2008
harbored 45 amino acid exchanges in the RT as compared
to themolecular CRF02 AGWTclone pBD15–6 (Figure 1)
(29). The first genotypic analyses were performed in March
2000 (Supplementary Table S1). Up to that point the pa-
tient had been subjected to therapies including the NRTIs
3TC, AZT, ddI, d4T (Supplementary Table S2). AZT re-
sistant HIV-1 strains typically possess TAMs to remove in-
corporated NRTIs as AZTMP or d4T, whereas the Q151M
discrimination pathway usually occurs upon administration
of other NRTIs like 3TC and ddI (6,10,11,14). The acces-
sory substitutions of the Q151MMDR complex help retain
the replication capacity or improve the discrimination effi-
ciency (11).
Sequencing of the patient isolate in March 2000 revealed
the presence of four TAMs (M41L, D67N, K70R, T215Y)
as well as twomutations of the Q151Mdiscrimination path-
way (F116Y and Q151M), whereas the K65Rmutation was
still missing (Supplementary Table S1). While the K70R
mutation was never discovered in later genotypic analyses,
K65R was first detected in June 2002. d4T was the only
NRTI applied from November 2000 to June 2002. K65R
confers resistance to d4T, TDF and possibly to 3TC, ddI
and ABC, but not to AZT (37–40). The presence of K65R
in combination with multiple TAMs is particularly interest-
ing. In HIV-1 subtype B, strains harboring K65R together
with multiple TAMs were only detected with a frequency of
<0.1%. What is more, K65R has never been found in com-
bination with T215F/Y, indicating that, in contrast to sub-
type AG, in subtype BK65R and the T215F/Ypathway are
not compatible (22). Furthermore, the accessory discrimi-
nation mutations A62V and V75I emerged, but F77I has
never been found (Supplementary Table S1).
In May 2003 the accessory TAM K219E occurred (Sup-
plementary Table S1) although at that point in time the
two NRTIs 3TC and TDF, which are not readily excised,
were used (Supplementary Table S2). TAM L210W, which
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Figure 1. Amino acid sequence alignment of subtype CRF02 AG WT and MR-RT. The positions of the amino acid substitutions in the MR-RT are
highlighted as colored boxes. Red boxes: TAMs; purple boxes: Q151M MDR pathway; cyan box: EFV resistance mutation; green box: K65R mutation;
yellow boxes: all othermutations. Compensatorymutationsmentioned in the text that are associatedwith themajorNRTI andNNRTI resistancemutations
described for subtype B are labeled with dots in the same color as the main mutations. The sequence alignment was performed using the program Lalign
(74). The polymerase domain is shown in gray, the connection subdomain in blue, and the RNase H domain in light brown.
in subtype B occurs occasionally in combination with other
TAMs, depending on theNRTIs used (8), could never be de-
tected. However, L210W has not been identified frequently
in the CRF02 AG subtype. This might at least in part be at-
tributed to the fact that in subtype B only one transversion
is needed to obtain the codon for Trp (TTG> TGG), while
in CRF02 AG two point mutations are required (CTG >
TGG) (41).
Concerning the AZT resistance pattern, the mutated
genotype remained almost stable since May 2003 (Sup-
plementary Table S1). Finally, in July 2008 four out of
six TAMs relevant for highly efficient AZTMP excision
(M41L, D67N, T215Y and K219E, missing K70R and
L210W) as well as four out of five discrimination muta-
tions (A62V, V75I, F116Y and Q151M, lacking F77I) were
present (26,42).
Characteristics of the multi-drug resistant RT
In addition to TAMs and discrimination mutations, MR-
RT possesses several mutations that are also present in drug
resistant subtype BRT, and are associated with resistance to
NRTIs andNNRTIs (Figure 1). Thesemutations have com-
pensatory effects and often lead to an improved replication
capacity of the virus, e.g. by restoring the polymerization ef-
ficiency of theRT.However, formany of them themolecular
function has not been investigated in detail (18).
Sequence comparisons of HIV-1 positive naı¨ve and
HAART treated patients revealed a correlation between
K20R and 3TC resistance and an association with TAMs,
while T39A appears to be associated with previous AZT
and d4T treatment and with the development of TAMs
(43). A62V and S68G restore the impaired nucleotide incor-
poration of the K65R mutation, thus improving the repli-
cation capacity of the virus (44). Similarly, the V75I ex-
change is compensatory for G190E, which emerges upon
NNRTI treatment. G190E confers a more than 50-fold
reduced sensitivity toward EFV but results in low poly-
merization activity (28,43). According to the HIV Drug
Resistance Database (http://hivdb.stanford.edu/), K101Q,
E138Q and exchanges at position V179 are also detected
in patients treated with EFV. However, in subtype B the
MR-RT exchange V179 toGly (V179G) has not been found
(http://hivdb.stanford.edu/). The P236L mutation charac-
teristic for delavirdine (DLV) resistance is absent in MR-
RT (http://hivdb.stanford.edu/). V118I occurs in combina-
tion with multiple TAMs (45). The polymorphism R172K
impairs AZTMP excision (46), while T165I is associated
with Q151M (47). G196E is also detected in NRTI resis-
tant viruses (48). The polymorphisms R211K and L214F
contribute to AZT resistance (49), however, in MR-RT
the reversal F214L was detected. The thumb subdomain
residues 255–286 of HIV-1 RT are important for proper
DNA binding (50). Polymorphisms in the thumb region
at positions 272, 277 and 286 have been shown to be as-
sociated with TAMs and therapy failure. Pro272, Arg277
and Thr286 are selected during NRTI combinations like
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d4T/ddI, d4T/3TC and abacavir (ABC), which have been
used in this study (51). In MR-RT only K277R was found
in combination with P272A, while at position 286 a Gly is
present in WT and MR-RT (Figure 1).
In subtype B several mutations in the connection subdo-
main (i.e. E312Q, G335C/D, N348I, A360I/V, V365I and
A376S) have been identified that significantly contribute to
AZT resistance by reducingRNaseH activity (52). Interest-
ingly, none of these mutations is present in MR-RT. How-
ever, the A400Tmutation as well as two of themutations ex-
isting in the RNase H domain (K512R, K530R) have been
shown to occur in subtype B during NRTI treatment (Fig-
ure 1) (53,54) (see below).
Fidelity
Several of the 45 amino acid exchanges, e.g. TAMs and
the Q151M complex, can be directly attributed to resis-
tance mutations. However, the enzyme also harbors com-
pensatory exchanges, e.g. S68G which has been shown to
improve the replicative capacity (Figure 1) (18). WT HIV-1
subtype B RT exhibits a rather low fidelity of replication,
which on the one hand is advantageous during antiretro-
viral therapy using NRTIs, on the other hand this can also
lead to rapid mutational changes resulting in resistance mu-
tations against the drugs applied. Discrimination of NRTIs
in resistant RTs and thus increased selectivity for the correct
dNTP is often correlated with a higher replication fidelity of
the RT (55).
Compared to the CRF02 AG WT RT, MR-RT harbors
several substitutions that have been implicated with an in-
crease in fidelity, i.e. K65R, V75I and Q151M (21,56,57).
Since subtype CRF02 AG WT RT exhibited a ca. 2-fold
higher polymerase activity thanMR-RT (Table 1), we chose
a fidelity assay in which effects of differences in catalytic ac-
tivities could be excluded. Thus only the incorporation of
the first matched or mismatched nucleotide was analyzed
(Figure 2). Despite the limitations of this assay, the data in-
dicate a higher fidelity of the MR-RT when non-templated
dCTP, dGTP or dTTP was offered. CRF02 AGWTRT in-
corporated those mismatched dNTPs almost as efficiently
as the correct dNTP, whereas significant differences could
be observed with theMR-RT, e.g. ATmatch versus TTmis-
match results in 80.6% versus 39.5% incorporation (Sup-
plementary Table S3). However, no differences could be de-
tected for the TA match and AA mismatch, neither for the
WT enzyme (89% match versus 93.9% mismatch) nor for
the MR-RT (89.7% match versus 91.2% mismatch incorpo-
ration).
HIV-1 RT preferentially inserts dATP mismatches in fa-
vor of other nucleotides (58,59). This appears to be an in-
trinsic property of the RT during reverse transcription, al-
though the biochemical background for this predisposition
is unknown (60). Our data suggest an increased fidelity of
the MR-RT which might contribute to the discrimination
of NTRIs versus the corresponding correct dNTP.
Polymerization properties
To better understand the substitutions’ impact on the prop-
erties ofMR-RT we further analyzed its polymerization be-
havior. Compared to the CRF02 AGWT RT, extension of
Figure 2. Fidelity of subtype CRF02 AGWT and MR-RT. Primer exten-
sion reactions were performed with 20 nMP/TDNA, 0.08 U of pyrophos-
phatase, 1.25 M of enzyme and 1.25 mM of the templated nucleotide
(dTTP) or 1.25 mM of the mismatched nucleotide (dATP) at 37◦C for
10 min. (A) Schematic representation of a primer extension reaction us-
ing T50dA as template. An end-labeled [32P]-P30/T50dA DNA/DNA sub-
strate was used to perform a templated extensionwith dTTP or amismatch
extension in the presence of dATP. Extensions using the other templates
were performed accordingly. Percentage of primer extension products af-
ter templated (light gray) andmismatched (dark gray) extensions of the P30
primer hybridized to the template T50dA (AA mismatch) (B), T50dC (CC
mismatch) (C), T50dT (TT mismatch) (D) T50dG (GG mismatch) (E) by
WT and MR-RT. Reaction products were separated on a 10% sequencing
gel and quantified. Each diagram depicts themean values and standard de-
viations (black bars) of three independent incorporation experiments. For
quantification of the extended products, the total amount of labeled DNA
per lane was set to 100%. P-values ≤ 0.05 represent statistically significant
differences to the WT protein (*P-value ≤ 0.05; **P-value ≤ 0.01;***P-
value ≤ 0.001).
a DNA primer on the heteropolymeric single strandedM13
substrate indicates a lower polymerization activity of the
MR-RT, since less primer is elongated (Figure 3). This is
also reflected in the reduced specific activities (SPACs) de-
termined on poly(rA)/oligo(dT) and the 3-fold higher dis-
sociation constant (KD) obtained for MR-RT in equilib-
rium titration experiments by measuring the fluorescence
of a fluorescent labeled DNA/DNAprimer/template (P/T)
(Table 1).
AZT resistance
Therapy of the patient started by administering AZT and
3TC (Supplementary Table S1) (26). The acquisition of
TAMs confers high-level resistance to AZT but not to 3TC.
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Table 1. Binding affinity for dsDNA and specific polymerization activities
KD (nM) SPAC1 (U/genzyme)
WT2 9.0 ± 0.6 6.3 ± 0.3
MR 28.7 ± 2.0 3.2 ± 0.2
MR-70R 62.0 ± 3.8 3.1 ± 0.2
MR-65K-70R 50.7 ± 3.3 3.7 ± 0.5
MR-70R-151Q 73.1 ± 3.7 3.2 ± 0.4
MR-65K-70R-151Q 50.2 ± 3.0 3.1 ± 0.2
AZTres-B 5.4 ± 0.4 2.9 ± 0.1
1specific activity, 1 U catalyzes 1 nmol of incorporated TMP within 10 min at 37◦C.
2WT = subtype CRF02 AG
Figure 3. DNA-dependent DNA polymerase activity of subtype
CRF02 AGWT and MR-RTs. Reactions were carried out at 37◦C for the
times indicated on top of the gel with 30 nM [32P]-P17/M13mp18, 200
M of each dNTP and 83 nM WT or MR-RT, or without RT (control)
in a reaction volume of 10 l. Extension products were analyzed by
denaturing gel electrophoresis on a 10% sequencing gel and visualized by
a phosphoimaging device. DNA size markers are shown on the left.
This might be the reason for the selection of the discrimi-
nation substitutions since according to the HIV Drug Re-
sistance Database (http://hivdb.stanford.edu/) Q151M and
the Q151M complex support low to moderate resistance to
3TC and efficient discrimination of various other NRTIs
which have also been used during ongoing therapy (Supple-
mentary Table S2) (26). In addition, the enzyme also carries
the codon K65R which was suggested to antagonize AZT
excision (22,23,61). However, the presence of the most rel-
evant substitutions of the two AZT pathways, i.e. T215Y
and Q151M, in addition to K65R raised the question as to
which pathway could still be used by MR-RT.
AZT excision and discrimination experiments with WT
andMR-RT showed thatMR-RT is capable of AZTTP dis-
crimination but not excision. To determine which amino
acids are essential for AZTTP excision in the context of the
MR-RT, we created several variants with amino acid sub-
stitutions that should further AZTMP removal. First, the
K70R mutation, which is the missing fifth TAM residue
promoting excision, was introduced (MR-70R). A second
variant was constructed which in addition harbors the re-
versal R65K (MR-65K-70R), to abrogate negative effects
of K65R on AZT excision. In a third variant, the pivotal
discrimination substitution Q151M was reversed to WT
and combined with K70R (MR-RT-70R-151M) to further
support the excision reaction. Finally, MR-RT-65K-70R-
151Qharbors all three codons that together should promote
AZTMP excision and abrogate discrimination. An AZT-
resistant HIV-1 subtype B RT (AZTres-B) encoding only the
five TAMs, but no other resistance mutations was included
as a positive control for AZTTP excision (62).
Analysis of the SPACs with a poly(rA)/oligo(dT) sub-
strate on a DNAP/T showed that the polymerization activ-
ities of theMR-RT derivatives reached values of ca. 3.1–3.7
U. Similarly, determination of the binding affinities revealed
comparable KD-values between ca. 28 and 73 nM, indicat-
ing that the substitutions had not significant effect on these
properties of the enzymes (Table 1). Thus the enzymes could
be used for excision and discrimination assays.
AZTMP removal assays with an AZTMP terminated
primer/template (P/T) substrate in the presence of 5 mM
ATP demonstrated that only the triple variant MR-65K-
70R-151Q exhibited significant AZTMP excision activity,
although it was still lower than that of the subtype B con-
trol RT AZTres-B (Figure 4).
To determine whether the RTs were capable of AZTTP
discrimination, 1 M of either AZTTP or TTP was of-
fered for incorporation (Figure 5). While no significant
differences were detectable for the incorporation of TTP,
MR-RT as well as MR-70R and MR-65K-70R exhibited
very low incorporation activities with AZTTP, indicating
discrimination capability. Only when the reversal M151Q
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Figure 4. AZTMP excision. AZTMP excision reactions with the
CRF02 AG WT and MR RTs were performed with 20 nM of a 5′ [32P]
end-labeled and AZTMP terminated [32P]-P30-AZTMP/T50substrate in the
presence of 5 mMATP, 0.01 U/l of pyrophosphatase and 600 nM RT as
indicated. Reactions were started by RT addition and stopped after 5 min
at 37◦C. After separation of the reaction products and educt by denaturing
gel electrophoresis, the bands were quantified densitometrically. The
total amount of AZTMP-terminated primer per lane was set to 100% to
calculate the percentage of excised AZTMP. Each diagram depicts the
mean values and standard deviations (black bars) of three independent
experiments. P-values ≤ 0.05 represent statistically significant differences
to the WT protein (***P-value ≤ 0.001).
Figure 5. Discrimination between AZTTP and TTP during nucleotide in-
corporation. For comparison of AZTMP versus TMP incorporation by
CRF02 AGWT and MR RTs, and AZTres-B RT, 100 nM of labeled [32P]-
P30/T50 substrate and 1 M of AZTTP or TTP were pre-incubated with
0.01U/l of pyrophosphatase for 5min at 37◦C.Reactions were started by
the addition of 200 nM of RT as indicated and performed for 30 s at 37◦C.
Control, reaction without enzyme. Educts and products were separated by
denaturing gel electrophoresis on a 10% sequencing gel.
of the major discrimination codon was present (MR-70R-
151Q, MR65K-70R-151Q, AZTres-B), discrimination be-
tween TTP and AZTTP was strongly impaired. The KM for
AZTTP of MR-RT compared with the two variants com-
prising the reverse codon M151Q, i.e. MR-70R-151Q and
MR-65K-70R-151Q, was 12-fold or 33-fold lower, respec-
tively (Table 2). This clearly confirms the ability of the MR-
RT for AZTTP discrimination in spite of the presence of
all five TAMs. This is also illustrated by a nearly 300-fold
higher KM-value for AZTTP of the MR-RT as compared
to the WT (Table 2).
Obviously, the Q151M pathway developed due to the ad-
ministration of drugs that could not be efficiently eliminated
by the excision pathway. Although analyses with subtype B
RT indicated that K65R and the TAM T215F/Y are not
compatible, i.e. they were not found in combination (22), we
could show that the MR-RT which harbors both residues
concomitantly exhibits polymerase and RNase H function
(see below) and resulted in a replicating virus that could be
isolated from the patient.
However, it was not sufficient for AZTMP excision to
occur even if all five TAMs were present (MR-70R), or if
in addition K65R (MR-65K-70R) or Q151M (MR-70R-
151Q) were reversed (Figure 4). Interestingly, probably due
to the presence of the resistance mutation K65R,MR-70R-
151Q was neither able of efficient AZTTP discrimination
nor AZTMP excision. Only the combination of both re-
versals of K65R and Q151M in the presence of all TAMs
(MR-65K-70R-151Q) resulted in AZTMP excision (Figure
4), albeit less efficient than with AZTres-B RT. This might
be due to several other mutations not directly involved in
AZT resistance, e.g. the polymorphism R172K or the ex-
change G190E, which are both present in MR-RT but not
in the WT. R172K was shown to decrease DNA binding
affinity and to suppress the excision mechanism by TAMs
(46). Furthermore,R172Kmight contribute to the observed
lower DNA binding affinities of the MR-RT variants. Al-
though G190E is a NNRTI resistance mutation (63), it is
often detected with V75I of the Q151M complex. G190E
severly impairs polymerization activities due to reposition-
ing of the primer, which in turn is antagonistic to excision
(28,64). Therefore, the presence of thesemutations could ex-
plain why MR-65K-70R-151Q is still less efficient in excis-
ing AZTMP than the AZTres-B RT.
Our data indicate that the two pathways are mutually ex-
clusive and that although four TAMs including T215Y are
present, only AZTTP discrimination by the Q151M com-
plex is functional, thus enabling the enzyme to exhibit high
level resistance against various NRTIs that have been ad-
ministered during therapy.
RNase H activities
Although the patient received only RT inhibitors targeted
against the polymerase domain, compared to the sub-
type CRF02 AG WT 11 amino acid substitutions were
detected in the connection subdomain (A322T, G324E,
D335G, V380I, A400T, M403T) and in the RNase H
domain (I469L, T470P, K512R, L520Q, K530R, S554N,
V556I) (Figure 1). In HIV-1 subtype B two of the muta-
tions, A400T and K512R, have been correlated with the oc-
currence of TAMs in a dose-dependent manner, being more
frequent as the number of TAMs increased (53). The fre-
quency of K530R is also increased in NRTI treated per-
sons (12.1% versus 1.1% in untreated isolates) (54). A400T
has been associated with increased AZTMP excision in sub-
types B and CRF01 AE (65). In the context of TAMs, sub-
type CRF01 AE appeared to be less susceptible to AZT
than subtype B, which was suggested to be due to re-
duced RNase H activities and improper positioning of the
primer/template in the RNase H domain (65).
Improper positioning of the substrate might also lead
to differences in the cleavage sites. To determine whether
the enzymes exhibited altered RNase H activities we per-
formed RNase H activity assays with a fluorescent labeled
RNA29/DNA29 using WT and MR-RT variants as well as
AZTres-B RT to uncover possible differences in RNase H ac-
tivities between subtype B and CRF02 AG (Figure 6). The
RT variants appeared to be less active than the WT on the
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Table 2. KM, vmax and KM/vmax values for AZTMP-incorporation
KM (nM) Vmax (nM/min) Vmax/KM (1/min) · 10−3
WT1 29.2 ± 9.8 11.8 ± 1 404.1 ± 139.9
MR 3585.5 ± 312.5 11.8 ± 0.4 3.3 ± 0.3
MR-70R-151Q 296.1 ± 19.6 12.8 ± 0.2 43.2 ± 2.9
MR-65K-70R-151Q 107.4 ± 15.4 13.2 ± 0.4 122.9 ± 18.0
1WT = subtype CRF02 AG
Figure 6. Qualitative RNase H assay. Autoradiogram of a typical RNase
H cleavage experiment. RNase H reactions with 100 nM 5′ labeled Cy5-
RNA29/DNA29 hybrid and RT variants at concentrations of (i) 33.3 nM,
(ii) 11.1 nM and (iii) 3.7 nM were performed for 10 min at 37◦C. RNA
ladder, Cy5-RNA29/DNA29 hybrid boiled, without RT, control, reaction
without RT. RNA size markers are shown on the left.
substrate used, while the cleavage pattern was not signifi-
cantly affected. Therefore, to better characterize the mutant
RT-associated RNase H function we measured their cat-
alytic efficiencies by determiningKM- and kcat-values (Table
3). We found that the MR-RTs’ RNase H activities are sig-
nificantly impaired as compared to the WT enzyme. In par-
ticular, although in some cases the RT variants showedKM-
values lower than the WT RT, all enzymes exhibited a sig-
nificantly lower kcat. Overall,MR-RT revealed a kinetic effi-
ciency (kcat/KM) comparable to WT RT, while the insertion
of the K70R codon resulted in a significantly lower RNase
H enzyme efficiency (Table 3). AnRNA39/DNA29 substrate
harboring the HIV-1 polypurine tract (PPT) sequence was
correctly cleaved by WT and MR-RT and its derivatives
(data not shown), indicating the variants can still create the
correct PPT RNA primer necessary for plus strand DNA
synthesis during reverse transcription. However, the lower
specific RNase H activity and strongly reduced catalytic ef-
ficiency of MR-70R could be one of the reasons why this
combination, harboring all five TAMs was not found in the
patient.
RNase H inhibitor testing
The occurrence of MR viruses diminishes virus drug sus-
ceptibility and undermines HAART, allowing MR viruses
to replicate with high viral loads. Similar to the CRF02 AG
isolate described here, such viruses often harbor resistance
mutations against a variety of NRTIs, NNRTIs as well as
protease inhibitors (26). HIV-1 RNaseH is an attractive ad-
ditional target for drug discovery and development, since it
is essential for reverse transcription during retroviral repli-
Figure 7. Chemical structures of HIV-1 subtype B RNase H inhibitors
cation. Several classes of HIV-1 RHIs have been developed,
which inhibit the RNase H of HIV-1 subtype B (66–69).
Thus we tested known inhibitors representing different in-
hibitor classes (Figure 7):
(i) a natural product isolated from Thuja plicata 2,7-
dihydroxy-4-isopropyl-cyclohepta-2,4,6-triene (-
Thujaplicinol, BTP), that binds the two divalent Mg2+
ions in the RNase H catalytic site (36);
(ii) (Z)-3-(2-(4-(3,4-dihydroxyphenyl)thiazol-2-
yl)hydrazono)indolin-2-one (NSC657589) which
is able to inhibit HIV-1 RT-associated RNA depen-
dent DNA polymerase (RDDP) as well as RNase H
activities, possibly by binding to a region between the
polymerase catalytic aspartate triad (Asp110, Asp185,
Asp186) and the NNRTI pocket, hence contiguous to
the NNRTI pocket but different from it (70);
(iii) the active site diketo acid derivative 6-[1-(4-
fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-
hexenoic acid ethyl ester (RDS1643) (71), the diketo
ester derivative E-ethyl-6-(1-(2-chlorobenzyl)-1H-
pyrrol-2-yl)-2,4-dioxohex-5-enoate (RDS1759) (72);
(iv) 2-(3,4-dihydroxyphenyl)-6,7,8,9-tetrahydro-3H-
cyclohepta[4,5]thieno[2,3-d]pyrimidin-4(5H)-one
(compound 29). Biochemical experiments suggest that
it binds at the HIV-1 RT p66/p51 interface (73).
Our data show that the RNase H activities of all RT en-
zymes can be inhibited by the different classes of inhibitors
at lowmicromolar or even nanomolar concentrations in the
case of BTP (Table 4), confirming that targeting RNase H
is a valid approach especially in the context of already com-
promised sensitivity to the majority of currently approved
drugs.
CONCLUSIONS
Characterization of MR-RT and its derivatives demon-
strates that the AZT discrimination pathway antagonizes
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Table 3. Kinetic analysis of RNase H activities
Specific RNase H
activity1 (U) KM (nM) kcat (min−1)
Efficiency kcat/KM
(min−1· nM−1)
WT2 14 114 ± 21 66 ± 9 0.48 ± 0.06
MR 53 46 ± 7 18.7 ± 1.8 0.40 ± 0.02
MR-70R 130 87 ± 14 7.8 ± 1.4 0.09 ± 0.001
MR-70R-65K 79 90 ± 17 12.9 ± 1.8 0.14 ± 0.003
MR-70R-151Q 159 236 ± 62 6.4 ± 0.2 0.028 ± 0.008
MR-70R-65K-151Q 74 80 ± 7 12.6 ± 2.3 0.15 ± 0.015
1pmol of enzyme needed for 1 nmol/h of product.
2WT = subtype CRF02 AG.
Table 4. Inhibition of HIV-1 subtype AG RTs by RNase H inhibitors
RNase H IC50 (M)1
BTP RDS1759 RDS1643 NSC657589 Compound 29
WT2 0.31 ± 0.02 19.5 ± 3.3 24.5 ± 4.3 1.79 ± 0.61 2.51 ± 0.14
MR 0.88 ± 0.07 18.6 ± 5.6 21.4 ± 6.9 1.74 ± 0.23 1.04 ± 0.45
MR-70R 0.34 ± 0.01 18.5 ± 4.4 16.6 ± 5.4 1.40 ± 0.23 1.35 ± 1.09
MR-70R-65K 0.81 ± 0.28 23.2 ± 3.3 17.3 ± 5.2 2.40 ± 0.17 1.70 ± 0.03
MR-70R-151Q 0.43 ± 0.17 28.1 ± 1.6 25.3 ± 6.7 2.64 ± 0.33 1.60 ± 0.90
MR-70R-65K-151Q 0.41 ± 0.25 21.5 ± 3.0 22.3 ± 1.3 3.42 ± 0.11 1.66 ± 0.32
AZTres-B 0.34 ± 0.01 69.5 ± 14.7 83 ± 20 13.8 ± 2.8 9.2 ± 2.5
1compound concentration able to inhibit 50% of RNase H enzymatic activity.
2WT = subtype CRF02 AG.
the excision mechanism, even if the TAMs relevant for ex-
cision are present. Analyses with subtype B RT indicated
that K65R and the TAM T215F/Y are not compatible in
the absence of the Q151M complex and were rarely found
if Q151M or Q151M and at least two additional mutations
of the complex were present. Thus, a strong functional an-
tagonism of K65R and T215F/Y in the presence of two
or more additional TAMs may exist (22). We show here,
that subtype AGMR-RT which harbors K65R, T215F and
three additional TAMs concomitantly is still functional as
a polymerase and RNase H. Moreover, in the presence of
the Q151M complex K65R does not lead to AZT sensi-
tivity. In the MR-RT, AZT resistance appears to be re-
tained via the discrimination pathway. Only if both codons
65 and 151 of the discrimination pathway were restored to
the WT residues (i.e. K65, M151), excision could occur, in-
dicating that both exchanges are essential to prevent ex-
cision. Our data show, that the two AZT resistance path-
ways are mutually exclusive and not additive. Obviously,
establishment of the M151Q complex is advantageous for
the virus during varying treatment regimens with chang-
ing NRTIs, since it is efficient against multiple NRTIs. Our
data might have important consequences for genotypic re-
sistance interpretation algorithms, e.g. the HIV Drug Re-
sistance Database (http://hivdb.stanford.edu/), which give
high AZT resistance mutation scores for Q151M occurring
in coexistence with the TAMs T215F and M41L. However,
we can show here, that these mutations do not create an ad-
ditive impact on AZT resistance.
Moreover, MR-RT also exhibits a much higher fidelity
than the WT RT, which further supports discrimination
against NRTIs. Although several mutations are present
in the RNase H domain, our results with various RHIs
demonstrate their inhibitory potential, implying that fur-
ther development, improvement and application of RHIs
could be a potent tool to combat multi-drug resistant HIV
strains.
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